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The description of a cell-free soluble anti-tumour
factor by Carswell et al. in 1975 (Proc Natl Acad
Sci USA, 72: 3666±3670) was followed by a long
series of experimental and clinical investigations
into the role of cell-free mediators in cancer
immunotherapy. These investigations included
research on the effects of macrophage-derived
eicosanoids (cycloxygenase and lipoxygenase de-
rivates of arachidonic acid) and of monokines
such as tumour necrosis factor-a, interleukin-1
and granulocyte ±monocyte±macrophage-colony
stimulating factor) and of lymphocyte products:
interleukins and interferons. The investigations
yielded information on the effects of various
factors on macrophage and T-cell activation in
vitro, determination of direct anti-tumour proper-
ties on animal and human tumour cells in vitro
and on therapeutic effectiveness in tumour-bear-
ing individuals either alone or in combination
with other therapeutic factors and their produc-
tion by tumour cells. During recent years much
effort has been dedicated towards the use of the
tumour cells transfected with cytokine genes in
the preparation of cancer vaccines. Cycloxygen-
ase products (prostaglandins) were usually as-
sumed to inhibit expression of anti-tumour
activity by macrophages and an increase in their
production in cancer patients was considered as a
poor prognostic index. Lipoxygenase (leuko-
trienes) products were assumed to exhibit anti-
tumour activity and to induce production of IL-1
by macrophages. Interleukins 2, 4, 6, 7, 12 and
the interferons were extensively tested for their
therapeutic effectiveness in experimental tumour
models and in cancer clinical trials. The general
conclusion on the use of cell-free mediators for
cancer immunotherapy is that much still has to
be done in order to assure effective and reprodu-
cible therapeutic effectiveness for routine use in
the treatment of human neoplasia.
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Introduction
The ￿eld of cancer immunotherapy began ap-
proximately 100 years ago with rather ‘naive’
attempts to use anti-tumour antibodies raised
in various animals for treatment in human
sarcoma patients.1,2 At around the same time
Coley was probably the ￿rst (1891, cited in
reference 3) to suggest that cell-free ￿ltrates of
bacteria might posses anti-tumour activities.
Macrophages are known to produce and secrete
derivates of arachidonic acid and cytokines
(such as TNF-a and Interleukin-1 (IL-1). Tand B
cells produced and released a long series of
interleukins; both macrophage and Tand B-cell
products are involved in the interaction be-
tween the immune system and tumour cells in a
number of ways: direct anti-tumour activity,
activation of immunocompetent cells in vivo
and/or in vitro, and changes in their production
in vivo in tumour-bearing hosts. Finally, it
was shown that tumour cells themselves
might secrete some of the above mentioned
products and develop a means to resist the anti-
tumour activity of various biologically active
products.
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macrophages and T -cell products against tumour
cells helped to devise certain immunotherapeu-
tic protocols ￿rst in experimental animal tu-
mour systems and afterwards in human
neoplasia. The immunotherapeutic protocols
were based on either treatment with cell-free
products alone or in combination with other
treatments. They also helped in devising ways
to activate in vitro immuno-competent cells for
therapeutic uses in vivo.
The aim of this review is to discuss the
potential involvement of cell-free mediators in
cancer immunotherapy. On reviewing their anti-
tumour activities it should be mentioned that
some of these mediators are also involved in
in￿ammatory processes and that their produc-
tion is closely interelated.
Eicosanoids and Cancer
Cycloxygenase (prostaglandins) and lipoxygen-
ase products have been used in experimental
tumour systems and are involved in human
neoplasia.
Prostaglandins
It has generally been assumed that prostaglan-
dins (especially PGE2) inhibit anti-tumour activ-
ity of macrophages. Thus a PGE2 inhibitor,
indomethacin, enhanced the macrophage cyto-
static activity in vitro against MOPC-315 murine
plasmacytoma cells.4 Indomethacin stimulation
of macrophage cytostasis was inhibited by
PGE2
5,6 and this enhancement of anti-tumour
activity was also reported in vivo against
Ehrlich murine tumour cells. 7- 10 The effect of
endogenous and exogenous prostaglandins on
macrophage functions was described: culture
conditions that caused increased PGE2 produc-
tion by activated macrophages resulted in an
inhibition of their tumoricidal activity whereas
production of high levels of PGE2 by resident
and elicited macrophages was associated with
an increase in their tumoricidal activity.11 In
another work,12 it was reported that a subcuta-
neous injection of polyacrylamide beads in mice
induced a population of immature macrophages
which became fully cytostatic to syngeneic
P815 plasmacytoma when stimulated in vitro
by LPS. Blocking of PGE synthesis by indometh-
acin prevented the effect of LPS and addition of
PGE2 did not reverse the indomethacin effect
but inhibited the macrophage-mediated cyto-
static activity.12 Suppression of macrophage-
mediated tumour cytotoxicity was correlated
with an increase in secretion of prostaglandin
from the macrophages of breast cancer pa-
tients.13,14 Elevated prostaglandin production in
human breast cancer was considered a marker
of high metastatic potential for neoplastic cells,
the increase in PG production occurred early in
the course of breast cancer and decreased later
in the course of tumour development.15 It
seems that PGE2 production by human mono-
cytes is by a subset of cells other than the cells
which produce IL-1.16 It should also be men-
tioned that cancer cells also produce PGE2 and
in this context it was reported that the amount
of PGE2 released by cancer cells which metasta-
sized into the liver of tumour-bearing rats was
higher than that of cells metastasizing into the
kidney.17 An increase in prostaglandin levels in
cancer patients was also reported:18 of plasma
prostaglandin F levels in cases of tumours of
the female genital tract and of plasma 6-oxo-
prostaglandin F1a in cases of gynecological
tumours.19,20
On the assumption that prostaglandins can
suppress the development and expression of
effector cells, clinical studies were initiated to
determine the effect of piroxicam (a prost-
aglandin antagonist) in patients with recurrent
unresectable squamous cell carcinoma or lym-
phoepithelial carcinoma of the head and neck.21
Although some improvement in immune reac-
tivity was noted, more studies to correlate the
improvement in immune reactivity with thera-
peutic effectiveness of either prostaglandin
antagonists alone or in combination with other
treatments are needed.21- 23 A paradoxical effect
of indomethacin on lymphokine-activated killer
cell (LAK) activity in cancer patients was
described: indomethacin enhanced LAK activity
in patients with no distant metastases but
depressed LAK activity in patients with such
metastases.24 Apparently, these effects of indo-
methacin are not related to the PGE inhibiting
property of this compound.24 Increased synth-
esis of prostaglandin by macrophages from
breast cancer patients was assumed to inhibit
macrophage mediated cytotoxicity.25
Leukotrienes
Leukotrienes (lipoxygenase pathway of arachi-
donic acid) are usually considered to enhance
the potential of the immune response.26,27 Thus,
leukotriene and indomethacin enhance addi-
tively the macrophage anti-tumour cytostatic
function.4,28 Leukotriene B4 (LTB4) was re-
ported to augment human monocyte cytotoxic
activity and enhance monocyte production of
hydrogen peroxide, IL-1 and TNF .26 5-Lipoxy-
genase activation was also described to facilitate
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leukotrienes of IL-1 production by human
monocytes was also described in other re-
ports.30,31 Lipoxygenase speci￿cally inhibited
indomethacin stimulation of anti-tumour macro-
phage cytostasis32 and reversed macrophage
cytostasis, induced by the calcium ionophore
A23187, towards P815 tumour cells in vitro.31
Leukotriene C4 was reported to be an essential
5-lipoxygenase intermediate in A23187-induced
macrophage cytostatic activity against P815
tumour cells.33 Products of the lipoxygenase
pathway were involved in human natural killer
cell cytoxicity.34
Cytokines
Immunocompetent cells reported to produce
and secrete cytokines involved in the reaction
of the organism to tumour cells were macro-
phages, Tand Bcells.
Macrophage-derived cytokines
Biologically active products described as being
involved in the interaction with tumour cells
were tumour necrosis factor-a (TNF-a) interleu-
kin-1 (IL-1) and granulocyte ±macrophage col-
ony stimulating-factor (GM-CSF).
TNF-a
The ￿rst description of TNF-a as a macrophage
product was made by Carswell et al.35 Since
then, several reviews have appeared which have
been concerned with the characterization and
properties of this cytokine.3,36- 38 The mechan-
ism and activity spectrum of TNF-a has been
the topic of several investigations: it was
reported that exposure of human cervical carci-
noma cells to Concanavlin A (ConA) increased
the total number of binding sites for rTNF-a but
blocked the transduction of the signal for the
cytotoxic response.39 MethA sarcoma cells were
found to be sensitive in vitro to human tumour
recombinant TNF-aand expressed low numbers
of TNF-a receptors.40 TNF-a (unlike INF-c or IL-
1a), induced regression of subcutaneous MethA
implants.40 It was assumed that the primary
lesion induced by TNF-a is vascular and the
mechanism(s) involved in generation of speci￿c
cell-mediated anti-tumour immunity induced by
the TNF-a treatment was not clear.41 It was
claimed that there are multiple pathways lead-
ing to resistance to TNF-a induced tumour cell
cytotoxicity, among them production of trans-
forming growth factors by tumour cells and
ampli￿ed expression of certain oncogenes.41
Apparently, viable activated monocytes produce
other lytic factors in addition to TNF-a and IL-1
because TNF-a and IL-1 associated with plasma
membranes of activated human monocytes lyse
only monokine-sensitive tumour cells whereas
viable activated monocytes lyse both monokine-
sensitive and monokine-resistant tumour cells.42
The killing of tumour cells by TNF-a was
assumed to involve internalization of this ligand
in the target cells.43 The anti-tumour effect of
TNF-a and of Interferon-c against MmB16 mur-
ine melanoma was potentiated by macrophage
colony-stimulating factor.44 The anti-tumour ac-
tivity of recombinant human TNF-SAM1 was
enhanced by connecting the TNF compound to
thymosin b4.45 TNFa acted synergistically with
IL-1 in inhibiting the growth of A375 cells.46 An
experimental study carried out in nude mice
showed that intratumoral injection of an adeno-
viral vector containing radiation inducible DNA
sequence of the Egr-1 promoter linked to a
cDNA encoding TNF-a (Ad.Egr-TNF) enhanced
the tumoricidal action of ionizing radiation in a
human epidermoid carcinoma xenograft.47 By
another experimental approach it was shown
that murine tumour cells transduced with the
gene for TNF-a, regressed unlike non-trans-
duced tumour cells after an initial phase of
tumour growth.48
The results in vitro and in vivo from experi-
mental tumour models which indicated the anti-
tumour activity of TNF-a, prompted initiation of
clinical trials devised to determine the therapeu-
tic effectiveness of TNF-a in human neoplasia.
Intravenous injection of TNF-a in 18 cancer
patients led to some clinical improvement in
three lymphoma patients.49 Recombinant TNF-a
was given in combination with TNF-c in phase I
trials in 36 patients with solid tumours. Side-
effects such as fatigue, fever and chills oc-
curred: in one patient with melanoma there
was a mixed response and in one patient with
mesothelioma there was transient clearance of
ascites from malignant cells.50 Disappointing
results were reported in a phase II study of
recombinant human TNF-a in 127 cancer pa-
tients. The conclusion of the authors was that:
‘‘rhuTNFa does not appear to have signi￿cant
anti-tumour activity’’.51 A similar conclusion was
made in a phase II trial of rTNF-a in 22 patients
with adenocarcinoma of the pancreas: ‘‘No
objective responses were observed’’.52 A phase
II study of recombinant TNF-a was also per-
formed in a group of 26 renal cell carcinoma
patients. The conclusion was: ‘‘rTNF given as
described, has only modest anti-tumour activity
in renal carcinoma and produces considerable
toxicity. We plan no further studies of rTNF in
this disease’’.53 In a phase I study including 16
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static cancer, there was evidence for anti-
tumour effect in two patients.54 The property of
TNF-a as an immunomodulator was reported:55
pretreatment of monocytes with IFN-a, IFN-c,
IL-1 or TNF-a resulted in enhanced human
monocyte toxicity.
Interleukin-1
The production, characterization and properties
of IL-1 have been summarized in several re-
views.56,57 It was stated that IL-1 is a key
mediator of host response to microbial invasion
and that it acts as a true hormone produced
during infection and in￿ammation.57 Human
recombinant IL-1 (hrIL-1) induced proliferative
responses of T cells in the presence of sub-
optimal concentrations of mitogen and doubled
the response to higher concentrations.57 Human
recombinant IL-1 induced release of IL-2 by
T cells and acted as a potent in￿ammatory
agent by inducing dermal ￿broblast PGE2 pro-
duction in vitro and of fever in rabbits and
mice.57 The overall conclusion from these data
was that IL-1 possesses both immunological
and in￿ammatory properties.57 Human Inter-
leukin-1 acted as a cytocidal factor for several
tumour cell lines58 and promoted human mono-
cyte-mediated tumour cytotoxicity.59 Human
monocytes stimulated with pneumococcal cell
surface components produced IL-1 but not TNF ,
thus showing independence of production of
the two cytokines.60 As mentioned already46 IL-1
acted synergistically with TNF-a against tumour
cells. IL-1a enhanced carboplatinum anti-
tumour activity against human ovarian cells in
vitro and in vivo.61 In an in vitro study with
human melanoma cell lines it was shown that
tumour cells which secrete IL-1 exhibited in-
creased adhesion to endothelial cells.62
Granulocyte ±m acrophage colony stimulating fac-
tor (GM-CSF)
The effect of intravenous and intraperitoneal
administration of GM-CSF was examined in a
phase I trial of 13 cancer patients refractory
to standard chemotherapy.63 Administration of
MG-CSF was well tolerated but no data were
provided on clinical improvement.63 In another
study, it was reported that administration of
GM-CSF in 24 patients with solid tumours
enhanced monocyte cytotoxicity against a
human colon carcinoma line but no data are
given on the effect on clinical course of the
disease.64
The partial and somehow disappointing re-
sults obtained in clinical trials with TNF-a may
be due to several factors:
· TNF-a can be administered only in small
amounts because higher amounts are toxic
and induce severe side effects.
· TNF-a is a relatively small molecule and as
such, is rapidly cleared after injection.
· It is possible that some human cells are
resistant to TNF-a or develop mechanism(s)
of defence against the anti-tumour activity of
TNF-a.
· Anti-tumour activity in vivo requires more
than one anti-tumour factor.
· TNF-a in vivo does not occur suf￿cient
concentration in its contact with tumour
cells.
In view of the results obtained in clinical
trials with TNF-a, experiments were undertaken
to use activated human macrophages or acti-
vated human peripheral blood for therapy.
It was assumed that macrophages can act
indiscriminately against immunogenic or non-
immunogenic tumours, and that they might
release monokines continuously in vivo (in
addition to TNF-a and/or IL-1) which would
be active against the tumour cells. It should
be mentioned in this context that activated
macrophages might release anti-tumour cyto-
static products unrelated to IL-1, TNF-a and
INF-a/b.65 Results of in vitro experiments
showed that peritoneal human macrophages
obtained from renal patients on continuous
ambulatory peritoneal dialysis (CAPD) can be
activated in vitro by LPS to express anti-tumour
activity and as such they acted in vivo against
a human tumour implanted subcutaneously
in nude mice.66 Similarly, human peripheral
blood cells from cancer patients, activated
in vitro by IFN-c and LPS, reacted against a
human tumour growing in nude mice.67 These
results prompted clinical trials with autologous
human peripheral blood monocytes activated in
vitro and reinjected in to the cancer pa-
tients.68,69 The therapeutic effectiveness of this
procedure was limited68,69 and probably more
clinical trials are required in order to improve
conditions for therapy with activated macro-
phages.
Lymphocyte-derived Interleukins
Interleukin-2
Interleukin-2 (IL-2) is one of the main products
of T cells and was extensively studied in the
context of its anti-tumour activity. IL-2 was
reported to increase human natural killer (NK)
cell activity in vitro and this activity was
partially reduced by monocytes due to PGE2
production.70 Murine lymphocytes cultured in
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tumour cells.71 The lytic activity was attributed
to the occurrence of lymphocyte activated killer
(LAK) cells Thy-1+ Lyt- 1-2+.71 The described
effects of IL-2 in enhancing anti-tumour activity
promoted a series of clinical trials devised to
determine the therapeutic effects of IL-2 in
cancer patients. It was found that of 106
patients with metastatic cancer receiving LAK
cells plus IL-2, eight had complete responses,
15 had partial responses and ten had minor
responses. 72 The same group of researchers
reported that autologous tumour in￿ltrating
lymphocytes (TIL), cultured in the presence of
IL-2, lysed melanoma tumour cells.73 Melanoma-
speci￿c cytolytic tumour lymphocytes derived
from TIL grown in the presence of IL-2, and
injected together with IL-2, induced tumour
rejection in vivo possibly by reacting against
the gp100 epitope.74 A phase I trial in a total of
31 evaluable patients with metastatic cancer of
the breast, gastric cancer, colorectal cancer,
melanoma, non-small cell lung cancer, osteosar-
coma or renal cancer, received a combined
treatment of IL-2, followed by TNF-a and indo-
methacin:75 two partial responses were seen (in
breast and renal cancer).75 In another clinical
trial, 16 patients with advanced renal cell
cancer (stage IV) received a combined treat-
ment of cyclophosphamide, INF-a and IL-2.76
Two patients had a partial response, two had a
minor response and three patients achieved
stable disease.76 The effect of IL-2 with or
without LAK cells was assayed in another group
of 71 patients with advanced renal cell
carcinoma.77 A low level of anti-tumour re-
sponse was detected and the addition of LAK
cells did not improve the response.77 IL-2
administration was found to prolong survival of
some metastatic renal cell carcinoma patients
with no or moderate HLA-II expression and/or
no or moderate macrophage presence in the
primary tumour, but was not effective in pa-
tients with both high HLA-II and high macro-
phage expression.78 Some potential uses of IL-2
treatment have been described: IL-2 and IL-7
augmented the cytolytic activity and the anti-
tumour killing spectrum of aCD3-induced acti-
vated killer cells, and such cells were suggested
for immunotherapy of non-immunogenic tu-
mours.79 Cytotoxicity of induced LAK cells
against human leukaemia was augmented in the
presence of either IFN-a, IFN-c or TNF-a in
cultures, and as such they might be more
effective in treating human leukaemia.80 Adop-
tive therapy of established pulmonary meta-
stases with LAK cells and recombinant IL-2 has
been reported.81 Adoptive therapy with highly
enriched NK cells was assumed to have a
potential use in leukaemia.82 It should be also
mentioned that LAK cells are apparently not a
unique cell type but a function of various types
of cells.83 Finally, one of the problems of IL-2
therapy is the toxicity of the compound: in this
context, it was suggested that the oxygen free-
radical scavenger, dimethythiourea, ameloriates
pulmonary permeability and vascular leak syn-
drome associated with multiple-dose IL-2 ther-
apy without inhibiting IL-2 induced anti-tumour
cytotoxicity.84 On the other hand, the tumour-
associated antigen 90K and the soluble IL-2
receptor were associated with poor prognosis
in human ovarian cancer.85 Another way of
promoting the anti-tumour activity of IL-2 was
by gene transfer into tumour cells. 86- 89 The use
of a human renal carcinoma line transfected
with IL-2 and/or INF-a gene has been suggested
for the preparation of live cancer vaccines.90
Combined treatment with granulocyte colony
stimulating factor and IL-2 increased the survival
time of nude mice bearing human ovarian
cancer cells.91
Interleukin-4
Interleukin-4 was ￿rst described as B-cell stimu-
latory factor. IL-4 was reported to inhibit
tumour growth of syngeneic mammary adeno-
carcinoma, plasmacytoma,92 and renal carci-
noma93 by using cytokine gene transfer into the
murine tumours. Repeated injections of small
amounts of IL-4 around the tumour draining
nodes of mice resulted in growth inhibition of
poorly immunogenic and non-immunogenic tu-
mours (cited in reference 94). Transfection of
IL-4 into tumour cells induced release of this
cytokine and it was effective, in vivo, against a
wide range of tumour cells implanted in nude
mice.92 Similarly, treatment of established mur-
ine renal cancer by tumour cells engineered to
secrete IL-4, induced speci￿c T -cell dependent
systemic immunity against the non-transfected
tumour.93 To my knowledge, IL-4 therapy has
not yet been tested in human neoplasia.
Interleukin-6 (INF-b2)
Interleukin-6 is induced in T cells by antigen
stimulation. Puri￿ed human recombinant (rIL-6)
mediated substantial reduction in the number of
tumours.95 Recombinant human IL-6 produced
in Escherichia coli inhibited the growth of
human breast carcinoma and leukaemia/lymph-
oma cell lines in vitro.96 Anti IL-6 receptor
antibody prevented muscle atrophy in Colon-26
adenocarcinoma bearing mice, thus suggesting
that this antibody could be a potential agent
against muscle atrophia in cancer cachexia.97 IL-
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inhibited growth of lung carcinoma98 and of
sarcoma.99 IL-6 gene transfected into Lewis Lung
Carcinoma tumour cells suppressed the malig-
nant phenotype and was effective against par-
ental metastatic cells.98 Mice rejecting murine
￿brosarcoma cells, transduced with retroviral
vectors containing the murine IL-6 gene and
secreting IL-6, exhibited a later resistance to
challenge with wild tumour cells.98 Aquisition
of the ability to synthesize endogenous IL-6
markedly accelerated the growth of weakly
tumorigenic rat urothelial cells, but did not
induce a tumorigenic phenotype in non-tumor-
igenic cells.100
Interleukin-7 (B/Tm aturation factor)
Murine plasmacytoma cells transfected with the
IL-7 gene produced IL-7 in vivo and were
completely rejected in syngeneic mice by a T -
cell dependent process.101
Interleukin-12
IL-12 has received considerable attention during
recent years as a strong anti-tumour agent: IL-12
was reported to react in vivo against B16F10
tumour-bearing mice and its anti-tumour effect
was inhibited by anti-IFN-c antibody; 102 IL-12-
transfected ￿broblast cells admixed with the
murine melanoma, BL-6, showed that local IL-12
expression suppressed tumour growth and pro-
moted development of speci￿c anti-tumour im-
munity;103 IL-12 engineered dendritic cells were
effective in vivo against murine tumour cells.104
In another report, it was shown that anti IFN-c
antibody blocked IL-12-mediated tumour regres-
sion in mice. 105 In view of the results obtained
from IL-12 therapy against murine tumours,
clinical trials were initiated to determine the
effect of IL-12 in human cancer. Phase I clinical
trials of IL-12 gene therapy were done by direct
injection of tumours with genetically engi-
neered autologous ￿broblasts. 106,107 Out of 13
cancer patients (six breast, ￿ve melanoma, and
two head and neck), signi￿cant reduction in
tumour size was observed in three patients with
melanoma and one with head and neck
cancer. 108
Interferon-a2b
A clinical trial was done in renal cancer and
melanoma patients by treatment with INF-a2b.
Of 12 melanoma patients, four patients showed
a partial response whereas eight patients pro-
gressed. 109 In the case of 35 patients with
advanced renal cancer, an increase in immune
response potential was observed.109 The conclu-
sion was that more studies are required to
determine the therapeutic effectiveness of INF-
a2b.109 A human renal carcinoma line trans-
fected with the IL-2 and/or the IFNa gene was
suggested for use in preparation of live cancer
vaccines.90
Interferon-c (IFN-c)
IFN-c was ￿rst described as an antiviral agent
and was among the ￿rst cytokines assayed for
therapeutic effectiveness in human neoplasia. In
one of the ￿rst clinical trials done in Hodgkin’s
disease patients it was reported that treatment
with IFN-c led to an extension of the disease-
free survival time.110 Complete or partial remis-
sion in multiple myeloma by IFN-c treatment
was also reported. 111 Remissions induced by
IFN-c were also reported in patients with lym-
phocytic lymphoma, 112 in cases of metastatic
breast cancer, 113 non-Hodgkin’s lymphoma112
and multiple myeloma. 113 However, in another
study in a group of non-small cell lung cancer
patients, INF-c treatment did not induce tumour
regression.114 A phase I trial on the effect of
IFN-c treatment was conducted in six patients
with lung cancer;115 systemic side effects such
as transient fever, nausea, headaches and
￿u-like symptoms were noted 115 but no data on
therapeutic effect were given.115 In a recent
in vitro study it was reported that human
carcinoma cell lines cultured with IFN-c ex-
pressed more CD80 and CD86 costimulatory
molecules and that this increase in expression
was inhibited by IL-10. 116 Transfer of the IFN-c
gene into murine neuroblastoma,117 ￿bro-
sarcoma, 118 adenocarcinoma,119 colon carci-
noma119 and lung carcinoma120 cell lines
induced tumour inhibition in syngeneic mice.
Human peripheral blood monocytes collected
from cancer patients were activated in vitro to
express anti-tumour activity in the presence of
IFN-c and LPS.67,68
Anti-tumour effects vs other
functions of cytokines
Some facts which should be considered in the
context of the anti-tumour activity of cytokines
are discussed below.
Relationship with in￿ amm atory functions
Macrophage-derived cytokines such as TNF-a
and IL-1 are also major in￿ammatory med-
iators.5,27,28,37,56,57 Human peritoneal macro-
phages from CAPD patients collected during
infectious peritonitis are ‘primed’ to produce
and secrete more TNF-a and IL-1 when cultured
in the presence of LPS.121,122 These data indicate
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Interactions in cytokine production
Production and release of various eicosanoids
and cytokines are closely interrelated.37 For,
example: production of IL-1, TNF-a and IL-6 by
human mononuclear cells was induced by
stimulatory agents such as LPS,36,56 LPS-induced
TNF-a production is inhibited by PGE2, 123 en-
dotoxin, TNF-a and IL-1 induce IL-6 production
in vivo;124 production of IL1 and TNF-a was
induced in human blood mononuclear cells by
LPS, whereas IL-6 suppressed the induction of
IL-1b and TNF-a by LPS or PHA.125
Production of eicos anoids and cytokines by
tumour cells
Production of eicosanoids and cytokines by
tumour cells may have an in￿uence on the
effect of these products on tumour develop-
ment: tumour cells might produce PGE2; 126 the
response of murine tumours to indomethacin
therapy was directly related to their ability to
produce prostaglandin;127 tumours from cachec-
tic mice produced both TNF-a and IL-1a in
vivo;128 a myeloma human cell line produced
both TNF-a and IL-6;129 leukaemic cells from
patients with acute myeloid leukaemia pro-
duced both IL-6 and IL-1.130 These are a few
examples; the relationship between the ability
of tumour cells to produce eicosanoids or
cytokines and development of cancer is not yet
clear.
Production of eicos anoids and cytokines in the
tumour-bearing host
During tumour growth in rats cycloxygenase or
thromboxane synthase was inhibited whereas
C5 and C12-lipoxygenases of the alveolar macro-
phages were activated.131 Macrophages derived
from tumour-bearing animals suppressed activa-
tion of T cells, of NK cells, of LAK cells and of
generation of tumoricidal activity in normal
syngeneic splenic macrophages in cultures sti-
mulated by LPS.132 The secretion of IL-1, TNF-a
but not of IL-6 was impaired in alveolar macro-
phages collected from tumour-bearing mice. 133
A decrease in production of IL-1 was also
reported in peritoneal macrophages collected
from sarcoma-bearing mice.134 Production of IL-
1 and TNF-a by tumour associated mononuclear
monocytes from cancer patients was examined
and showed that production IL-1 was sup-
pressed whereas production of TNF-a was not
affected. 135 LPS induced TNF-a production was
impaired in macrophages from breast cancer
patients, 136 but increased in patients with malig-
nant brain tumours. 137 An example of correla-
tion between production of TNF-a and PGE2 by
peripheral blood monocytes was seen in pa-
tients with bladder cancer: these patients had
either higher TNF-a production or higher PGE2
production.138
Cell-free mediators as cancer
therapeutic agents
In vitro activation of cells for
immunotherapy
Activation of autologous human peripheral
blood monocytes by culture in the presence of
LPS and IFN-c was assayed with the aim of
inducing anti-tumour cytotoxic activity in the
treated monocytes and to use such activated
cells for immunotherapy.68,69 Clinical trials re-
ported limited success.68,69 Induction of LAK
cells, and later of activated tumour in￿ltrating
lymphocytes (TIL) by culturing in the presence
of IL-2 was also suggested in a series of
reports. 71- 74 Clinical trials were carried out in
groups of cancer patients; the results obtained
indicated some therapeutic bene￿t in melanoma
and renal carcinoma with approximately 10%
clinical improvement in patients treated with
both IL-2 and LAK cells.72
Direct administration of cytokines in
cancer patients
As previously mentioned the results of treat-
ment with TNF-a were disappointing; injection
of IL-2 with or without LAK cells was proble-
matic due to the toxicity of the agent; the effect
of IL-2 in patients with squamous cell carcinoma
of the head and neck was limited to temporary
regression of the tumours. 139 Another approach
suggested was to counteract the activity of
PGE2 by using a PGE inhibitor: while some
improvement in immunological functions was
observed no data are yet available on the
therapeutic effectiveness of this treatment.21
Transfection of tumour cells with
cytokine genes
This approach has been extensively investigated
during recent years, ￿rstly in experimental
tumour models and later in clinical trials. The
transfected tumours released the appropriate
cytokine in vitro and in some cases induced T -
cell mediated speci￿c anti-tumour immunity.
Partial success was observed in terms of tumour
regression and clinical improvement. 140- 142 Pro-
ductive transfer of the IL-2 gene was shown for
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and acute leukaemia cell lines.86,108,139- 141 Sev-
eral reviews have been published on the role of
cytokines in cancer therapy: in a review pub-
lished in 1989 it was concluded ‘‘The clinical
results obtained with cytokines (INF-a, IL-2,
TNF-a, GM-CSF , G-CSF) expected to show direct
tumoristatic or tumoricidal effects have been
disappointing’’. 143 A more optimistic view was
expressed in another review: ‘‘local presence of
cytokines, either injected repeatedly at the
tumour site or released by cytokine-engineered
tumour cells, arouses immunogenicity in appar-
ently nonimmunogenic spontaneous tumours’’
and as such they might indicate ‘‘potential use
of cytokines as a component of new tumour
vaccines’’.144 In another review, it was con-
cluded: ‘‘Clinical applications [of cytokines] are
progressing, but many trials must follow to
assess precisely the multitude of potential uses
of these molecules’’.94 Finally, in a recent review
it was concluded: ‘‘Although several years will
probably be required to establish the true
impact of the gene-transfer modalities ... tech-
nological advances have opened prospects for
the management of cancer patients’’.142
Concluding Remarks
The ‘golden’ era on the role of cytokines in the
￿ght against cancer started with the description
by Carswell in 1975 of tumour necrosis factor.35
Since then, various aspects of the interaction
between eicosanoids, macrophage and lympho-
cyte cytokines and tumour state have been
described and investigated. The various topics
of investigation included:
· direct effects in vitro and in vivo of eicos-
anoids and cytokines on tumour cells in
experimental and clinical trials;
· activation of monocytes, macrophages and
lymphocytes in vitro by cytokines for use in
autologous cancer patients;
· effect of tumour state in experimental sys-
tems and human neoplasia on the production
and release of eicosanoids and cytokines;
· therapeutic effectiveness of combined treat-
ment with activated immunocompetent cells
and cytokines;
· role of secretion of eicosanoids and cytokines
by tumour cells in the interaction between
the tumour cells and the tumour-bearing host;
· therapeutic effectiveness of tumour cells
transfected with cytokine genes. It is assumed
that transfected tumour cells are more immu-
nogenic and as such they induce a T cell
mediated response against the wild type non-
transfected tumour. They might also secrete
cytokines in vivo which react against the
tumour cells.
Marked progress has been made during recent
years on the interaction between macrophage
and lymphocyte products and tumour cells, and
on their possible role in immunotherapy against
cancer. However, many more clinical trials are
required before these agents can be used in
routine therapy of human neoplasia.
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